Drug · DIN 02242518
ACTONEL
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since January 4, 2019; first marketed July 25, 2000.
- Drug Identification Number (DIN)
- 02242518
- Company (DIN owner)
- Allergan Pharma Co.Markham, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risedronic acid M05BA07
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) | 5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 3, 2017: NOC 19621New Drug Submission (NDS) · Change to the DIN owner Removing the 75mg strength Change in Part III to the 2014 Patient Mediciation Information (PMI) format and changes to the package inserts and product labels
- May 1, 2017: NOC 19224Supplement to a New Drug Submission (SNDS) · Update to the product monograph regarding osteonecrosis of the jaw (onj) in response to an advisement letter
- February 18, 2010: NOC 11062New Drug Submission (NDS) · Manufacturer name change
- July 17, 2000: NOC 1444Supplement to a New Drug Submission (SNDS) · New indication: treatment and prevention of postmenopausal osteoporosis, new strength
Other DINs named ACTONEL
- DIN 02246896 · Marketed
- DIN 02316838 · Marketed
- DIN 02239146 · Cancelled Post Market
- DIN 02297787 · Cancelled Post Market